{"success":true,"data":{"pressRelease":{"id":"132476","rtpr_id":"nPreqPT8Ra","ticker":"IONQ","exchange":"NYSE","all_tickers":["IONQ"],"title":"QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery","author":"PR Newswire","published_at":"2026-09-01T12:00:15.519Z","article_body":"QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug\nDiscovery\nPR Newswire\n\nPALO ALTO, Calif., Sept. 1, 2026\n\nJoint test on IonQ Forte hardware lands within 4% of benchmark, clearing the\nchemical-accuracy bar for enzyme active-site modeling via Amazon Braket\n\nPALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a\ntechnology demonstration of a hybrid quantum-classical chemistry workflow\nusing its Promethium® platform and IonQ's Forte trapped-ion quantum computer\nvia Amazon Braket.\n\n\n\nThe demonstration modeled the heme active site of cytochrome P450nor, a nitric\noxide reductase in the cytochrome P450 superfamily — the same superfamily\nwhose monooxygenase members carry out most human drug metabolism. By pairing\nGPU-accelerated classical pre-processing in Promethium with quantum\nmeasurements on IonQ Forte, the workflow calculated electrostatic interaction\nenergy within 0.5 kcal/mol (~4%) of classical benchmarks. This falls well\ninside the 1 kcal/mol threshold for chemical accuracy and delivers more than\ndouble the accuracy of the standard classical mean-field method. For the\nbiopharma industry, more accurately calculating electrostatic interaction\nenergy, a major factor in how tightly a drug candidate binds to its target, at\ncomplex metal centers such as the iron site in P450nor, could improve\ncandidate ranking and help identify metabolic risks earlier in the\ndrug-discovery process.\n\n\"Running the same hybrid workflow on IonQ's trapped-ion architecture,\nfollowing our recent demonstration on other quantum hardware, shows that\nPromethium's approach to combining classical and quantum computing is not tied\nto a single type of quantum hardware,\" said Dr. Kin-Joe Sham, Co-Founder and\nCOO at QC Ware. \"We believe this hardware-agnostic approach gives researchers\nflexibility as quantum computing continues to mature.\"\n\n\"Every month spent advancing a drug candidate on flawed metabolic data is\nwasted time and mounting risk,\" said Scott Millard, Chief Business Officer at\nIonQ. \"QC Ware and IonQ have shown that hybrid quantum-classical workflows can\npredict certain binding behavior accurately enough for discovery teams to\nconfidently rank candidates and catch toxicity risks early. We believe that's\nreal quantum impact on real health outcomes. I can't wait to see what this\npartnership delivers.\"\n\nTechnical Highlights:\n* Promethium Preprocessing: Promethium built and preprocessed a complex\n115-atom model of the P450nor active site containing over 1,000 molecular\norbitals. It automatically isolated the strongly correlated region down to a\n4-orbital active space mapped onto 8 qubits, which IonQ Forte measured in a\nsingle basis before returning results for Promethium to compute final\ninteraction energies classically.\n* Hardware Architecture: IonQ Forte's all-to-all qubit connectivity enabled\ncomplex two-qubit entangling gates to execute as designed without the routing\noverhead or additional error typical of limited-connectivity architectures.\n* Biopharma Impact: Accurately predicting binding energy at iron sites in\nenzymes like P450nor could enable pharmaceutical researchers to better rank\ndrug candidates and identify metabolic risks earlier in the R&D pipeline.\nSupported in part by Amazon Web Services (AWS) cloud compute credits, the\ndemonstration highlights how QC Ware's cloud-native Promethium® platform can\npotentially allow classical GPU clusters to seamlessly connect with cloud\nquantum computing resources on Amazon Braket.\n\nAvailable today, Promethium's GPU-native architecture enables researchers to\napply quantum chemistry across larger molecular systems and more compounds\nthan has traditionally been practical. For selected workloads, Promethium runs\ndemanding calculations up to 20× faster than conventional CPU-based DFT\nplatforms, helping researchers generate molecular-level insights in hours\ninstead of weeks and accelerating decision-making across drug discovery,\ncatalysis, and materials science.\n\nMedia contact: kj.sham@qcware.com \n\nAbout QC Ware\n\nQC Ware is a quantum computing software company. We are developing\napplications that unlock the power of quantum computing for drug discovery,\nmaterial design and other industry verticals. Our Promethium platform provides\nGPU-accelerated quantum chemistry for molecular modeling and drug discovery,\nhelping customers to make better discovery decisions today while exploring the\nhybrid quantum-classical workflows of tomorrow. QC Ware also organizes and\nhosts Q2B quantum computing conferences in Japan, Europe and the United\nStates.\n\nAbout IonQ\n\nIonQ, Inc\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=3803950653&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fionq.com%252F%26esheet%3D54451094%26newsitemid%3D20260316477473%26lan%3Den-US%26anchor%3DIonQ%252C%2BInc%26index%3D7%26md5%3D0818ffbedc6dbad8c4d1611ac94c2a0f&a=IonQ%2C+Inc).\n[NYSE: IONQ] is the world's leading quantum platform and foundry - delivering\nintegrated quantum solutions across computing, networking, sensing, and\nsecurity. IonQ's newest generation of quantum computers, the IonQ Tempo, is\nthe latest in a line of cutting-edge systems. Earlier systems have helped\ncustomers and partners including Amazon Web Services, AstraZeneca, and NVIDIA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=2329274946&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.ionq.com%252Fnews%252Fionq-speeds-quantum-accelerated-drug-development-application-with%26esheet%3D54568606%26lan%3Den-US%26anchor%3DAmazon%2BWeb%2BServices%252C%2BAstraZeneca%252C%2Band%2BNVIDIA%26index%3D2%26md5%3D01bdaebe76912a4097387943d94d15d7&a=Amazon+Web+Services%2C+AstraZeneca%2C+and+NVIDIA) achieve\na 20x performance increase over previous quantum solutions and accelerate\ninnovation in drug discovery, materials science, financial modeling,\nlogistics, cybersecurity, and defense. In 2025, the company achieved 99.99%\ntwo-qubit gate fidelity, setting a world record in quantum computing\nperformance\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=3140385695&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fionq.com%252Fnews%252Fionq-achieves-landmark-result-setting-new-world-record-in-quantum-computing%26esheet%3D54568606%26lan%3Den-US%26anchor%3Dsetting%2Ba%2Bworld%2Brecord%2Bin%2Bquantum%2Bcomputing%2Bperformance%26index%3D3%26md5%3Dcd2c9fd48587a4276bc37aaa73b82b5c&a=%C2%A0setting+a+world+record+in+quantum+computing+performance). \n\nHeadquartered in College Park, Maryland, IonQ has operations across North\nAmerica, Latin America, EMEA, and APAC. Our quantum computing services have\nbeen available through all major cloud providers since 2021, while we also\nmeet the needs of networking and sensing customers across land, sea, air, and\nspace. IonQ is making quantum platforms more accessible and impactful than\never before. Learn more at \n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=564867677&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttp%253A%252F%252Fionq.com%26esheet%3D54451094%26newsitemid%3D20260316477473%26lan%3Den-US%26anchor%3DIonQ.com%26index%3D12%26md5%3D4df0d4d379d0c2e8a7182c1ca24d655c&a=%C2%A0)IonQ.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=486669513&u=http%3A%2F%2Fionq.com%2F&a=IonQ.com).\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements relating to QC Ware's\nexpectations, hopes, beliefs, intentions or strategies regarding the future.\nForward-looking statements may be identified by the use of words such as\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\"\n\"forecast,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"project,\" \"seek,\" \"should,\"\n\"will,\" \"would\" and similar expressions that predict or indicate future events\nor trends or that are not statements of historical matters, but the absence of\nthese words does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the impact of hybrid quantum-classical chemistry workflows on the\ndrug discovery process and the potential for Promethium to drive such impact.\nThese statements are based on various assumptions and on the current\nexpectations of QC Ware's management and are not predictions of actual\nperformance. These forward-looking statements are subject to a number of risks\nand uncertainties, including changes in business, market, financial, political\nand legal conditions; the rapid evolution of quantum computing and flaws or\nerrors in Promethium or flaws in or misuse of quantum computing in general;\nand risks related to working with quantum hardware providers.\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery-302866098.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1181486/qcware-logo-blue-twoline-Logo.jpg?id=OA2922840\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreqPT8Ra","title":"QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery","author":"PR Newswire","ticker":"IONQ","created":"2026-09-01T12:00:15.519Z","tickers":["IONQ"],"exchange":"NYSE","article_body":"QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug\nDiscovery\nPR Newswire\n\nPALO ALTO, Calif., Sept. 1, 2026\n\nJoint test on IonQ Forte hardware lands within 4% of benchmark, clearing the\nchemical-accuracy bar for enzyme active-site modeling via Amazon Braket\n\nPALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a\ntechnology demonstration of a hybrid quantum-classical chemistry workflow\nusing its Promethium® platform and IonQ's Forte trapped-ion quantum computer\nvia Amazon Braket.\n\n\n\nThe demonstration modeled the heme active site of cytochrome P450nor, a nitric\noxide reductase in the cytochrome P450 superfamily — the same superfamily\nwhose monooxygenase members carry out most human drug metabolism. By pairing\nGPU-accelerated classical pre-processing in Promethium with quantum\nmeasurements on IonQ Forte, the workflow calculated electrostatic interaction\nenergy within 0.5 kcal/mol (~4%) of classical benchmarks. This falls well\ninside the 1 kcal/mol threshold for chemical accuracy and delivers more than\ndouble the accuracy of the standard classical mean-field method. For the\nbiopharma industry, more accurately calculating electrostatic interaction\nenergy, a major factor in how tightly a drug candidate binds to its target, at\ncomplex metal centers such as the iron site in P450nor, could improve\ncandidate ranking and help identify metabolic risks earlier in the\ndrug-discovery process.\n\n\"Running the same hybrid workflow on IonQ's trapped-ion architecture,\nfollowing our recent demonstration on other quantum hardware, shows that\nPromethium's approach to combining classical and quantum computing is not tied\nto a single type of quantum hardware,\" said Dr. Kin-Joe Sham, Co-Founder and\nCOO at QC Ware. \"We believe this hardware-agnostic approach gives researchers\nflexibility as quantum computing continues to mature.\"\n\n\"Every month spent advancing a drug candidate on flawed metabolic data is\nwasted time and mounting risk,\" said Scott Millard, Chief Business Officer at\nIonQ. \"QC Ware and IonQ have shown that hybrid quantum-classical workflows can\npredict certain binding behavior accurately enough for discovery teams to\nconfidently rank candidates and catch toxicity risks early. We believe that's\nreal quantum impact on real health outcomes. I can't wait to see what this\npartnership delivers.\"\n\nTechnical Highlights:\n* Promethium Preprocessing: Promethium built and preprocessed a complex\n115-atom model of the P450nor active site containing over 1,000 molecular\norbitals. It automatically isolated the strongly correlated region down to a\n4-orbital active space mapped onto 8 qubits, which IonQ Forte measured in a\nsingle basis before returning results for Promethium to compute final\ninteraction energies classically.\n* Hardware Architecture: IonQ Forte's all-to-all qubit connectivity enabled\ncomplex two-qubit entangling gates to execute as designed without the routing\noverhead or additional error typical of limited-connectivity architectures.\n* Biopharma Impact: Accurately predicting binding energy at iron sites in\nenzymes like P450nor could enable pharmaceutical researchers to better rank\ndrug candidates and identify metabolic risks earlier in the R&D pipeline.\nSupported in part by Amazon Web Services (AWS) cloud compute credits, the\ndemonstration highlights how QC Ware's cloud-native Promethium® platform can\npotentially allow classical GPU clusters to seamlessly connect with cloud\nquantum computing resources on Amazon Braket.\n\nAvailable today, Promethium's GPU-native architecture enables researchers to\napply quantum chemistry across larger molecular systems and more compounds\nthan has traditionally been practical. For selected workloads, Promethium runs\ndemanding calculations up to 20× faster than conventional CPU-based DFT\nplatforms, helping researchers generate molecular-level insights in hours\ninstead of weeks and accelerating decision-making across drug discovery,\ncatalysis, and materials science.\n\nMedia contact: kj.sham@qcware.com \n\nAbout QC Ware\n\nQC Ware is a quantum computing software company. We are developing\napplications that unlock the power of quantum computing for drug discovery,\nmaterial design and other industry verticals. Our Promethium platform provides\nGPU-accelerated quantum chemistry for molecular modeling and drug discovery,\nhelping customers to make better discovery decisions today while exploring the\nhybrid quantum-classical workflows of tomorrow. QC Ware also organizes and\nhosts Q2B quantum computing conferences in Japan, Europe and the United\nStates.\n\nAbout IonQ\n\nIonQ, Inc\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=3803950653&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fionq.com%252F%26esheet%3D54451094%26newsitemid%3D20260316477473%26lan%3Den-US%26anchor%3DIonQ%252C%2BInc%26index%3D7%26md5%3D0818ffbedc6dbad8c4d1611ac94c2a0f&a=IonQ%2C+Inc).\n[NYSE: IONQ] is the world's leading quantum platform and foundry - delivering\nintegrated quantum solutions across computing, networking, sensing, and\nsecurity. IonQ's newest generation of quantum computers, the IonQ Tempo, is\nthe latest in a line of cutting-edge systems. Earlier systems have helped\ncustomers and partners including Amazon Web Services, AstraZeneca, and NVIDIA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=2329274946&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fwww.ionq.com%252Fnews%252Fionq-speeds-quantum-accelerated-drug-development-application-with%26esheet%3D54568606%26lan%3Den-US%26anchor%3DAmazon%2BWeb%2BServices%252C%2BAstraZeneca%252C%2Band%2BNVIDIA%26index%3D2%26md5%3D01bdaebe76912a4097387943d94d15d7&a=Amazon+Web+Services%2C+AstraZeneca%2C+and+NVIDIA) achieve\na 20x performance increase over previous quantum solutions and accelerate\ninnovation in drug discovery, materials science, financial modeling,\nlogistics, cybersecurity, and defense. In 2025, the company achieved 99.99%\ntwo-qubit gate fidelity, setting a world record in quantum computing\nperformance\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=3140385695&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fionq.com%252Fnews%252Fionq-achieves-landmark-result-setting-new-world-record-in-quantum-computing%26esheet%3D54568606%26lan%3Den-US%26anchor%3Dsetting%2Ba%2Bworld%2Brecord%2Bin%2Bquantum%2Bcomputing%2Bperformance%26index%3D3%26md5%3Dcd2c9fd48587a4276bc37aaa73b82b5c&a=%C2%A0setting+a+world+record+in+quantum+computing+performance). \n\nHeadquartered in College Park, Maryland, IonQ has operations across North\nAmerica, Latin America, EMEA, and APAC. Our quantum computing services have\nbeen available through all major cloud providers since 2021, while we also\nmeet the needs of networking and sensing customers across land, sea, air, and\nspace. IonQ is making quantum platforms more accessible and impactful than\never before. Learn more at \n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=564867677&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttp%253A%252F%252Fionq.com%26esheet%3D54451094%26newsitemid%3D20260316477473%26lan%3Den-US%26anchor%3DIonQ.com%26index%3D12%26md5%3D4df0d4d379d0c2e8a7182c1ca24d655c&a=%C2%A0)IonQ.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764715-1&h=486669513&u=http%3A%2F%2Fionq.com%2F&a=IonQ.com).\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements relating to QC Ware's\nexpectations, hopes, beliefs, intentions or strategies regarding the future.\nForward-looking statements may be identified by the use of words such as\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\"\n\"forecast,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"project,\" \"seek,\" \"should,\"\n\"will,\" \"would\" and similar expressions that predict or indicate future events\nor trends or that are not statements of historical matters, but the absence of\nthese words does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the impact of hybrid quantum-classical chemistry workflows on the\ndrug discovery process and the potential for Promethium to drive such impact.\nThese statements are based on various assumptions and on the current\nexpectations of QC Ware's management and are not predictions of actual\nperformance. These forward-looking statements are subject to a number of risks\nand uncertainties, including changes in business, market, financial, political\nand legal conditions; the rapid evolution of quantum computing and flaws or\nerrors in Promethium or flaws in or misuse of quantum computing in general;\nand risks related to working with quantum hardware providers.\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery-302866098.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1181486/qcware-logo-blue-twoline-Logo.jpg?id=OA2922840\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-01T12:00:15.568430094Z","server_sent_at_ms":1788264015568},"received_at":"2026-09-01T12:00:15.655Z","source_url":null},"analysis":{"id":"121380","press_release_id":"132476","analysis_json":{"industry":{"label":"Technology Hardware, Storage & Peripherals","sector":"Information Technology"},"redFlags":[],"eventType":"partnership","narrative":"IonQ and QC Ware successfully demonstrated a hybrid quantum-classical workflow for drug discovery that achieved chemical accuracy, calculating electrostatic interaction energy within 4% of classical benchmarks.\n\nThe test utilized IonQ's Forte system with 8 qubits to model a 115-atom active site of an enzyme, delivering results within the 1 kcal/mol threshold required for high-precision drug candidate ranking.\n\nExecutives highlighted that this capability allows researchers to identify metabolic risks earlier in the pipeline, marking a step toward practical quantum utility in biopharma.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"IonQ hardware clears key 'chemical accuracy' benchmark in drug discovery demo with QC Ware."},"keyFigures":{"customDimensions":{"qubit_count":8,"model_atom_count":115,"active_space_orbitals":4,"molecular_orbital_count":1000,"promethium_speedup_vs_cpu":"20x","accuracy_deviation_percent":"4%","accuracy_deviation_kcal_mol":"0.5","chemical_accuracy_threshold_kcal_mol":"1"}},"quotedText":"Every month spent advancing a drug candidate on flawed metabolic data is wasted time and mounting risk","namedEntities":{"people":[{"name":"Dr. Kin-Joe Sham","role":"Co-Founder and COO at QC Ware"},{"name":"Scott Millard","role":"Chief Business Officer at IonQ"}],"products":["IonQ Forte","Promethium","Amazon Braket","IonQ Tempo","cytochrome P450nor"],"companies":[{"name":"IonQ","ticker":"IONQ"},{"name":"QC Ware","relationship":"partner"},{"name":"Amazon Web Services","ticker":"AMZN","relationship":"partner"},{"name":"AstraZeneca","ticker":"AZN","relationship":"customer"},{"name":"NVIDIA","ticker":"NVDA","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The joint demonstration clears the 'chemical accuracy' threshold for drug discovery modeling, a significant technical validation of IonQ's hardware capabilities in a high-value commercial application."},"tickerRelevance":{"others":[{"ticker":"AMZN","relevance":"partner"},{"ticker":"AZN","relevance":"partner"},{"ticker":"NVDA","relevance":"partner"}],"primary":"IONQ"},"globalImportance":25,"audienceRelevance":45,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"technical-validation-milestone","sectorWeight":"quantum-computing-niche"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"IonQ and QC Ware successfully demonstrated a hybrid quantum-classical workflow for drug discovery that achieved chemical accuracy, calculating electrostatic interaction energy within 4% of classical benchmarks.\n\nThe test utilized IonQ's Forte system with 8 qubits to model a 115-atom active site of an enzyme, delivering results within the 1 kcal/mol threshold required for high-precision drug candidate ranking.\n\nExecutives highlighted that this capability allows researchers to identify metabolic risks earlier in the pipeline, marking a step toward practical quantum utility in biopharma.","key_figures":{"customDimensions":{"qubit_count":8,"model_atom_count":115,"active_space_orbitals":4,"molecular_orbital_count":1000,"promethium_speedup_vs_cpu":"20x","accuracy_deviation_percent":"4%","accuracy_deviation_kcal_mol":"0.5","chemical_accuracy_threshold_kcal_mol":"1"}},"named_entities":{"people":[{"name":"Dr. Kin-Joe Sham","role":"Co-Founder and COO at QC Ware"},{"name":"Scott Millard","role":"Chief Business Officer at IonQ"}],"products":["IonQ Forte","Promethium","Amazon Braket","IonQ Tempo","cytochrome P450nor"],"companies":[{"name":"IonQ","ticker":"IONQ"},{"name":"QC Ware","relationship":"partner"},{"name":"Amazon Web Services","ticker":"AMZN","relationship":"partner"},{"name":"AstraZeneca","ticker":"AZN","relationship":"customer"},{"name":"NVIDIA","ticker":"NVDA","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T13:30:16.029Z","global_importance":25,"audience_relevance":45,"importance_components":{"tickerTier":"mid-cap","eventGravity":"technical-validation-milestone","sectorWeight":"quantum-computing-niche"}},"durationMs":493281,"modelName":"glm-4.7"}}